# Amendments to the Drawings:

The three attached replacement sheets containing new corrected drawings replace Figures 6A, 6B, 6C and 6D filed on September 12, 2001 and April 19, 2004. The changes in new corrected Figures 6A, 6B and 6C over original Figure 6 as filed on June 12, 2001 are shown in the three annotated sheets, which introduces the SEQ ID Nos. directly in the figure.

Attachment:

Three (3) Replacement Sheets containing Figures 6A, 6B and 6C.

Three (3) Annotated Sheets Showing Changes in Figures 6A, 6B and 6C over

original Figure 6 as filed.

### REMARKS

The Examiner has required new corrected drawings in a communication dated August 25, 2004. Specifically, the Examiner stated that:

the sequences depicted in Figures 6A-6D do not correspond to the description of Figure 6 in the specification. In particular, while the description of Figure 6 recites "(SEQ ID Nos: 6-25, 20, 21, 26-43, 65, 66, 44-63, 67, 64 respectively)," a review of the sequences of Figures 6A-6D (as compared to Applicant's Sequence Listing) reveals that this order does not in fact correspond to the order of the sequences depicted in proposed Figures 6A-6D.

Accordingly, in response Applicants submit new corrected Figures 6A, 6B and 6C, contained in the three Replacement Sheets of drawings, which replace the drawings submitted on September 12, 2001. Changes in the new corrected Figures 6A, 6B and 6C over original Figure 6 as filed on June 12, 2001 are shown in the three Annotated Sheets Showing Changes. The amendment over original Figure 6 as filed has been made merely to introduce the SEQ ID Nos. directly in the figure, which eliminates the confusion in the order of the sequences that was noted by the Examiner.

Since the SEQ ID Nos. are now directly contained in Figures 6A-6C, Applicants have amended the specification to delete the references to SEQ ID Nos. in the figure caption and to update reference to Figures 6A-6C. No new matter has been added with this amendment. Applicants also submit a Sequence Listing which reflects the SEQ ID Nos. in the new corrected drawings, in compliance with 37 C.F.R. §§ 1.821 through 1.825.

Applicants respectfully request that the amendments and remarks made herein be entered and made of record in the file history of the instant application.

Respectfully submitted,

Date: October 25, 2004

By: A. Coruzzi 30,742

Laura A. Coruzzi (Reg. No.)

By: 40,258

T. Christopher Tsang (Reg. No.)

JONES DAY

222 East 41st Street

New York, New York 10017-6702

(212) 326-3939

Enclosure

# Appln. No. 09/880,732 Amendment dated October 25, 2004 Response to Drawing Requirement of August 25, 2004 otated Sheet Showing Changes

									R	esp /	ons \ni	e t no
	Tm=63-64C				Tm=61-63C					•		
zyme activity	CYPwt(+)A2624, 22mer,54%GC, Tm=63-64C	CYPwt (+) A2624 (A) 30-3'NH2	CYPwt (+) A2625 (A) 30-3'NH2	CYPwt (+) A2625b (A) 30-3'NH2	CYPmut (+) A2624,21 mer,57%GC, Tm=61-63C	CYPmut (+) A2624 (A) 30-3'NH2	CYPmut (+) A2625 (A) 30-3'NH2	CYPmut (+) A2625b (A) 30-3'NH2		Wild Type(+)	Mut (+)	
1. 'A' Allele, CYP2D6'3, A21337 deletion, Frameshift resulting in zero enzyme activity	2637 5'- GCTAACTGAGCACAGGATGACC -3' NH2	5'- GCTAACTGAGCACAGGATGACC(A)30 -3' NH2	5' - CTAACTGAGCACAGGATGACC(A)30 -3' NH2	5' - CTAACTGAGCACAGGATGAC(A)30 -3' NH2	5'- GCTAACTGAGCAC-GGATGACC -3'NH2	5'- GCTAACTGAGCAC-GGATGACC(A)30 -3' NH2	5' - CTAACTGAGCAC-GGATGACC(A)30 -3' NH2	5'- CTAACTGAGCAC-GGATGAC(A)30 -3' NH2	-2612	SEQ ID NO:14   5' - GCTGGATGAGCTGCTAACTGAGCACAGGATGACCTGGGACCCAGCCCAGCC -3'	SEQ ID NO:15/5'- GCTGGATGAGCTGCTAACTGAGCAC-GGATGACCTGGGACCCAGCCCAG	
1. 'A' Allele,	SEQ ID NO:6	SEQ ID NO:7	SEQ ID NO:8	SEQ ID NO:9	SEQ ID NO:10	SEQ ID NO:11	SEQ ID NO:12	SEQ ID NO:13		SEQ ID NO:14	SEQ ID NO:15/	

	13	
	CYPwt(-)B1922 (C/A to mut at base 5) & CYPmut(+)B1922 (A/C to mut at base 13	
	at ]	
	mut	
	to	
Σ.	(A/C	
ivit	22	
act	)B19	
zyme	1t (+	
enz	YPm	
zerc	ر لا	
in	e 5)	
ing	bas	
sult	at	
t re	mut	
G1934A, Spliceing defect resulting in zero enzyme activity	A to	1934
λg d	(0)	7
ceir	922	
Spli	-)B1	
₽A,	Pwt (	
1193	CY.	
4,0	pe .	
YP2D6*	Pro	
CYP	. wt	
le,	A	
Alle		
'B' Allele,		
2.		



FIGURE 6A

# Appln. No. 09/880,732 Amendment dated October 25, 2004 Response to Drawing Requirement of August 25, 2004 Annotated Sheet Showing Changes

-2702	28 CYPwt (+) C2691, 22mer, 55%GC, Tm=60C	29 CYPwt (+) C2691 (A) 30-3'NH2 CYPwt (+) C2691 (A) 30-3'NH2	30   CYPwt (+) C2692 (A) 30-3' NH2	31 \ S'- GCAGAGATGGAGGTGAGAGTG -3' NH2 CYPmut(+)C2691, 21mer, 57%GC, Tm=60C	32   CYPmut (+) C2691 (A) 30-3'NH2 S GCAGAGATGGAGGTGAGAGTG(A) 30 -3'NH2	33 \ S'- CAGAGATGGAGGTGAGAGTG(A)30 -3' NH2 CYPmut(+)C2692 (A)30-3'NH2	SEQ ID NO:34 3'- TGACTCCGGAAGGACCGTCTCTCCACTCTCACCGACGGTGCCAC -5' Wild Type(-) SEQ ID NO:35 3'- TGACTCCGGAAGGACCGTCTCTACCTCCACTCTCACCGACGGTGCCAC -5' Mut (-)
	SEQ ID NO:28	SEQ ID NO:29	SEQ ID NO:30	SEQ ID NO:31	SEQ ID NO:32	SEQ ID NO:33	SEQ ID NO:34 SEQ ID NO:35

3. 'C' Allele, CYP2D6\*9, G2702-A2704 deletion, decreased enzyme activity

FIGURE 6B

		Pred
	A. wt Probe - CYPWt(-)E3009 (T/C to mut at base 5) & CYPMut(+)E3009 (C/A to Wt at base 15) $_{2023}$	CYPwt(-)E3009, 19mer,53%GC, Pred
ctivity	(C/A TO W	(-)E3009,
3C, H324P amino acid change results in zero enzyme activity	て(+) 近300岁	CYPwt
ts in zer	) & CYPMU	
ange resul	at base 5	
acid ch	C to mut	AGGC -5'
324P aminc	) E3009 (T/C	CGAGTACTAGGATGTAGGC -5'
A3023C, H	- CYPWt(-	NH2 3'- CGAGT
'E' Allele, CYP2D6*7, A3023	, wt Probe	NH2
Allele,	Α.	Q ID NO:36
<u>.</u> Б		

			3023		
	SEQ ID NO:36		NH2 3'- CGAGTACTAGGATGTAGGC -5'	U	CYPwt(-)E3009, 19mer,53%GC, Pred Tm=5
	SEQ ID NO:37		NH2 3'- (A)30CGAGTACTAGGATGTAGGC -5'	J	CYPwt(-) E3009(A)30-3'NH2
	SEQ ID NO:38		5'- GCTCATGATCCTACCTCCG -3'NH2	O	CYPmut(+)E3009,19mer,58%GC,Pred Tm=590
	SEQ ID NO:39		5' - GCTCATGATCCTACCTCCG(A)30 -3'NH2	0	CYPmut (+) E3009(A)30-3'NH2
		-2998	8		
	SEQ ID NO:40		5' - TGGGGCCTCCTGCTCATGATCCTACATCCGGATGTGCAGC   GTGAGCCCATC -3'	GAGCCCATC -3'	Wild Type(+)
	SEQ ID NO:41		5'- TGGGGCCTCCTGCTCATGATCCTACCTCCGGATGTGCAGC   GTGAGCCCATC -3'	GAGCCCATC -3'	Mut (+)
			-30	-3038-Intron Start	
3		B. CYPwt(	B. $ ext{CYPwt}(-)  ext{E3018}$ (T/C to mut at base 14) and $ ext{CYPmut}(+)  ext{E3018}$ (C/T to wt at base 6)	mut(+)E3018 (C/1	to wt at base 6)
	SEQ ID NO:42		NH2 3' - GGATGTAGGCCTACACGTC -5'		CYPwt(-)E3018,19mer,58%GC,Tm=60
	SEQ ID NO:43		5'- CCTACATCCGGATGTGCAG -3'		CYPwt(+)E3018- Target
	SEQ ID NO:44		5'- CCTACCTCCGGATGTGCAG -3' NH2	NH2	CYPmut (+) E3018, 19mer, 63%GC, Tm=62C
	SEQ ID NO:45		3'- GGATGGAGGCCTACACGTC -5'		CYPmut(-) E3018- Target
		-2998	81		
	SEQ ID NO:46		5' - TGGGGCCTCCTGCTCATGATCCTACATCCGGATGTGCAGC   GTGAGCCCATC -3'	GAGCCCATC -3'	Wild Type(+)
	SEQ ID NO:47		5'- TGGGGCCTCCTGCTCATGATCCTACCTCCGGATGTGCAGC GTGAGCCCATC -3'	GAGCCCATC -3'	Mut (+)

-3038-Intron Start





## Appln. No. 09/880,732 Amendment dated October 25, 2004 Response to Drawing Requirement of August 25, 2004 Annotated Sheet Showing Changes

# CYPwt(-) G1840(A)30-3'NH2 CYPmut(+)G1840(A)30-3'NH2,18mer, 61%GC, Tm=57 -3' enzyme activity CYPwt(+)T1785, 18mer,67%GC, Trn=59-61C CYPwt(+)T1785 (A)30-3'NH2 CYPwt(+)T1786 (A)30-3'NH2

CYPwt(+)G1840(A)30-3'NH2,18mer,67%GC, Tm=60

Allele, CYP2D6\*6, T1795 deletion, Frameshift resulting in zero enzyme activity Ļ

Exon 3 end- |-1846

GTGCCGCCTTCGCCACTCC | GGTGGGTGATGGGCAGAAGGGCCACAAAGCGGG -3' GTGCCGCCTTCGCCACTCC | TGTGGGTGATGGGCAGAAGGGCACAAAAGCGG -3'

5' - CACTCCTGTGGGTGATGG(A)30 -3' NH2

CYP2D6\*8, G1846T, Stop codon, zero enzyme activity

Allele,

Ď

FIGURE 6C

5' - CACTCCGGTGGGTGATGG(A)30

(A) 30GTGAGGCCACCACTACC

3′-

NO:48 NO:49

H

SEQ

5′-

ID NO:51 ID NO:52

ID NO:50

CYPwt(+)T1785, 18mer,67%GC, Trn=59-61C	CYPwt (+) T1785 (A) 30-3'NH2	CYPwt (+) T1786 (A) 30-3'NH2	CYPmut(+)T1785, 17mer,71 %GC, Tm=58-60C	CYPmut(+)T1785 (A)30-3'NH2	CYPmut (+) T1786 (A) 30-3'NH2		Wild Type(+)	Mut (+)
5'- GCTGGAGCAGTGAC -3' NH2	5'- GCTGGAGCAGTGGGTGAC(A)30 -3' NH2	5'- CTGGAGCAGTGGGTGAC(A)30 -3' NH2	5'- GCTGGAGCAG-GGGTGAC -3' NH2	5'- GCTGGAGCAG-GGGTGAC(A)30 -3' NH2	5'- CTGGAGCAG-GGGTGAC(A)30 -3' NH2	-1773	SEQ ID NO:59 / 5'-GGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCT	SEO ID NO: 60 5' -GGGCAAGAAGTCGCTGGAGCAG-GGGTGACCGAGGAGGCCGCCTGCCT -3'
SEQ ID NO:53	SEQ ID NO:54	SEQ ID NO:55	SEQ ID NO:56	SEQ ID NO:57	SEQ ID NO:58		SEQ ID NO:59	SEQ ID NO: 60

designs was to find region somewhere between the PCR primers were it would be easy to discriminate between 2D6 and 7. 2D6/2D7/2D8 Controls - The 2D6/7/8 probes were designed in the 1600 region of the 2D6 gene. The purpose of the its two pseudogenes, 2D7 and 2D8. The purpose of the designs is to demonstrate that the PCR amplicon is from the gene, not one of the pseudogenes.

SEQ ID NO:61	_	5'- GACCAGGGGAGC-ATAGG(A)30-3' NH2	CYP2D6wt(+)1607(A)30-3'NH2
SEQ ID NO:62		5' - GACCTTGTGGAGCGCCAG(A)30-3' NH2	CYP2D7wt(+)1607(A)30-3'NH2
SEQ ID NO:63		5'- GACCAGGAAAAGC-ACAGG(A)30-3' NH2	CYP2D8wt(+)1607(A)30-3'NH2
SEQ ID NO:64		5' - GACCAGGAAAAGC-ACAGGG(A)30-3' NH2	CYP2D8wt(+) 1607b (A)30-3'NF
		-1603	
SEQ ID NO:65	2,	- GGGAGACCAGGGGAGC-ATAGGGTTGGAGTGGGTGGT -3'	2D6 (+)
SEQ ID NO:66	Š,	- GGGAGACCTTGTGGAGCGCCAGGGTTGGAGTGGGTGGC -3'	2D7 (+)
SEQ ID NO:67	2,	- GGGAGACCAGGAAAAGC-ACAGGGTTGGAGTGGGCGGC -3'	2D8(+)
)			

Pos/Neg Control probes- These probes were designed as true positive and negative control probes. They consist 5' Biotin the same semi-random sequence, with the positive control probe having a . . of

_				
	SEQ ID NO:68	S,	Biotin-	ATCATTCCAATCA
ح	SEQ ID NO:69		5'-	ATCATTCCAATCA



